Home / Genomics and Cellular Research / Webinar - Broaden your applications with magnetic bead conjugation

Webinar - Broaden your applications with magnetic bead conjugation

Magnetic beads (or superparamagnetic particles) are one of the most versatile tools in molecular biology for easy and effective isolation of biomolecules. They incorporate tiny (20 to 30 nm) particles of iron oxides, such as magnetite (Fe3O4), which give them superparamagnetic properties. Whether you are purifying antibodies from a crude extract, coating beads with specific antibodies, or binding targets to the beads, it is important to choose a bead that suits your application. Sometimes, the required chemistry is not readily available or does not perform as intended and it is necessary to modify the magnetic properties, coatings or functional groups through customization or conjugation.

Join our webinar hosted by Tom Lyons (MChem) to discuss the technology behind magnetic bead chemistry and the advantages of conjugation and customization to optimize results. From protein and nucleic acid sample preparation to labelling and detection products, hear how these modifications can streamline your genomics workflow and expand your molecular diagnostic applications.

Learning objectives:
• Discuss the technology behind magnetic bead chemistry.
• Understand the range of surface chemistries and sizes available to meet different application requirements.
• Review how magnetic bead customization and conjugation can help to streamline the genomics workflow and expand the range of molecular diagnostic applications available

Tom Lyons
Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
Tom Lyons is a Custom Projects Leader at Cytiva, managing custom Sera-Mag™ formulations and conjugation projects. Since graduating from the University of East Anglia with a Masters in Analytical Chemistry with Forensic Sciences in 2008, Tom has gained experience in many research and development roles including British BioCell where he developed lateral flow immunodiagnostic devices and Binx Healthcare (formerly Atlas Genetics), where he developed enzyme stabilization formulations and managed the bulk reagent formulating process. Tom is trained in PRINCE2 project management with a focus on the transfer to manufacture of formulations for InVitro Diagnostic Devices with CE and FDA regulator frameworks.